MYAMBUTOL Drug Patent Profile

When do Myambutol patents expire, and when can generic versions of Myambutol launch?

Myambutol is a drug marketed by Kanchan Hlthcare and is included in one NDA.

The generic ingredient in MYAMBUTOL is ethambutol hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the ethambutol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Myambutol

A generic version of MYAMBUTOL was approved as ethambutol hydrochloride by EPIC PHARMA LLC on November 30^th, 1999.

Summary for MYAMBUTOL

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	34
Drug Prices:	Drug price information for MYAMBUTOL
What excipients (inactive ingredients) are in MYAMBUTOL?	MYAMBUTOL excipients list
DailyMed Link:	MYAMBUTOL at DailyMed

See drug prices for MYAMBUTOL

Recent Clinical Trials for MYAMBUTOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Cape Town	Phase 2
Aurum Institute	Phase 2
Singapore Immunology Network	Phase 2

See all MYAMBUTOL clinical trials

Pharmacology for MYAMBUTOL

Drug Class

Antimycobacterial

US Patents and Regulatory Information for MYAMBUTOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-001	Approved Prior to Jan 1, 1982	AB	RX	Yes	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Kanchan Hlthcare	MYAMBUTOL	ethambutol hydrochloride	TABLET;ORAL	016320-003	Approved Prior to Jan 1, 1982	AB	RX	Yes	Yes

MYAMBUTOL Market Dynamics, Patent Status, Pricing, and Financial Trajectory

Last updated: August 4, 2026

Myambutol, the brand name for ethambutol hydrochloride, is a mature tuberculosis drug with limited branded revenue and durable clinical demand. Its commercial value comes from inclusion in multidrug tuberculosis regimens, not from brand pricing power. The active ingredient is off-patent, generic competition is extensive, and no meaningful biosimilar risk exists because ethambutol is a small-molecule medicine. Financial performance depends on public-health procurement, tuberculosis incidence, manufacturing continuity, and government stockpiling.

What is Myambutol and how is it used?

Myambutol contains ethambutol hydrochloride, an oral antimycobacterial agent used with other drugs to treat tuberculosis and selected infections caused by Mycobacterium avium complex. It is not generally used as monotherapy because tuberculosis treatment requires combination therapy to limit resistance development.[1]

The drug inhibits arabinosyl transferases involved in mycobacterial cell-wall synthesis. The principal safety concern is optic toxicity, including reduced visual acuity and color-vision changes. Treatment commonly requires baseline and periodic visual monitoring, particularly in patients with renal impairment or prolonged exposure.[1]

Attribute	Myambutol
Active ingredient	Ethambutol hydrochloride
Drug class	Antimycobacterial
Primary indication	Pulmonary and extrapulmonary tuberculosis as part of combination therapy
Other use	Mycobacterium avium complex regimens
Dosage forms	Oral tablets; strengths vary by market
FDA regulatory category	Small-molecule prescription drug
Biosimilar pathway	Not applicable
Commercial maturity	Long-established, genericized product

How large is the market for ethambutol?

The addressable market is tied to tuberculosis treatment volumes rather than to a conventional branded pharmaceutical market. The World Health Organization estimated that approximately 10.8 million people developed tuberculosis globally in 2023, including about 1.25 million deaths.[2] Ethambutol is commonly included in the initial treatment regimen for drug-susceptible tuberculosis, although final regimen selection depends on resistance testing, clinical factors, and national guidelines.

The market has two distinct segments:

1. Public-sector tuberculosis programs in high-burden countries.
2. Hospital, clinic, and pharmacy demand in lower-incidence countries.

Public-sector procurement accounts for a large portion of global volume. Buyers often purchase fixed-dose combinations containing rifampicin, isoniazid, pyrazinamide, and ethambutol rather than separate Myambutol-branded tablets. This reduces the commercial relevance of the standalone brand.

Demand drivers

Ethambutol demand is supported by:

• Persistent global tuberculosis incidence.
• Continued use in first-line drug-susceptible tuberculosis regimens.
• Use in selected nontuberculous mycobacterial infections.
• Government buffer-stock requirements.
• Treatment of tuberculosis in correctional, refugee, and high-density health-care settings.
• Growth in drug-resistance surveillance and diagnostic capacity.

Demand is constrained by:

• Declining tuberculosis incidence in several developed markets.
• Substitution by fixed-dose combination products.
• Public procurement price pressure.
• Reduced use when optic toxicity risk is elevated.
• Treatment changes based on molecular susceptibility testing.
• Low brand loyalty among institutional buyers.

What is Myambutol’s FDA and Orange Book status?

Myambutol is an old FDA-approved product, and ethambutol hydrochloride is widely available through generic approvals. FDA labeling identifies ethambutol tablets as a prescription treatment used in combination with other antituberculosis agents.[1]

The Orange Book is the relevant source for current FDA-listed patents, exclusivity, and therapeutically equivalent products. For a drug with this age and generic penetration, the commercial record is consistent with a product that has no material remaining new-drug patent exclusivity.[3]

Regulatory issue	Myambutol assessment
New chemical entity exclusivity	Expired decades ago
Current branded exclusivity	No material exclusivity identified
Paragraph IV exposure	Commercially immaterial for the original product because generic entry is established
Orange Book patent leverage	No meaningful current patent barrier expected
Generic substitution	Established
FDA approval pathway for competitors	Abbreviated New Drug Application pathway
Biosimilar competition	Not applicable

The precise list of marketed products and therapeutic equivalents can change as FDA approvals are updated. Commercial analysis should distinguish the historical Myambutol brand from currently marketed ethambutol hydrochloride products.

When does Myambutol lose exclusivity?

Myambutol lost practical market exclusivity many years ago. Ethambutol was introduced in the 1960s, and any original composition-of-matter protection expired long before the current generic market developed. The relevant commercial question is no longer the loss of exclusivity date. It is whether a supplier can maintain reliable, low-cost production and qualify for public procurement.

No significant modern patent estate is generally associated with the core ethambutol molecule. Potentially relevant intellectual-property rights could arise around:

• Fixed-dose combinations.
• Modified dosage forms.
• Manufacturing processes.
• Packaging or delivery systems.
• Specific treatment regimens.
• Formulations for special populations.

Those rights would not restore exclusivity to the original Myambutol tablets unless they covered the marketed product and survived validity and infringement challenges.

What patents protect Myambutol and ethambutol?

The core active ingredient is a legacy small molecule with no commercially meaningful remaining composition-of-matter protection. Public-domain chemistry and long-standing generic manufacture have removed the principal patent barrier.

Patent category	Current commercial importance
Ethambutol composition of matter	Expired
Original tablet formulation	Expired or no longer commercially restrictive
Fixed-dose combinations	May apply to particular combinations, but generally does not protect standalone ethambutol
Manufacturing patents	May exist for particular processes, but usually do not prevent alternative production
Method-of-use patents	Limited relevance because tuberculosis treatment methods are established
Packaging patents	Low barrier and product-specific
Pediatric or special-population claims	Potentially narrow and unlikely to create broad exclusivity

Paragraph IV litigation is therefore not a central current risk for Myambutol. Generic manufacturers typically compete through abbreviated approvals, procurement qualification, manufacturing scale, and regulatory compliance rather than through litigation over a live brand patent estate.

What formulations are protected by Myambutol patents?

The commercially important formulation is the conventional oral tablet. There is no clear basis for treating the standard Myambutol tablet as protected by an active, high-value formulation patent.

Fixed-dose combinations create the main formulation opportunity. Ethambutol may be combined with rifampicin, isoniazid, and pyrazinamide in products intended to reduce pill burden and improve adherence. These products can have separate regulatory files, manufacturing requirements, and, in some markets, formulation or process rights. Their commercial value is driven primarily by procurement eligibility and inclusion in treatment guidelines.

A formulation patent covering a particular combination would not necessarily block generic standalone ethambutol. The two products can occupy different regulatory and procurement channels.

How does Myambutol compare with competing tuberculosis drugs?

Ethambutol is one component of a broader tuberculosis treatment market. It competes indirectly with other antituberculosis agents based on regimen selection rather than direct brand substitution.

Drug	Primary role	Market position	Main commercial constraint
Ethambutol	Initial combination therapy	Mature, generic, high-volume public-health product	Low pricing and optic-toxicity monitoring
Rifampicin	Core first-line agent	Essential and high-volume	Resistance, drug interactions, procurement dependence
Isoniazid	Core first-line agent	Essential and low-cost	Hepatotoxicity and resistance
Pyrazinamide	Initial intensive phase	High-volume combination component	Hepatotoxicity and tolerability
Rifapentine	Selected preventive and treatment regimens	More differentiated	Higher cost and narrower use
Bedaquiline	Drug-resistant tuberculosis	Higher-value specialty product	Resistance management, access, and procurement policy
Linezolid	Drug-resistant tuberculosis	Adjunctive or alternative use	Toxicity and cost

Ethambutol is less commercially differentiated than rifapentine or bedaquiline. Its strategic value is operational: programs need dependable supply at low cost.

What is the financial trajectory for Myambutol?

Standalone Myambutol revenue is not publicly disclosed in a consistent, audited format. The product is generally sold within diversified pharmaceutical portfolios, and public companies usually report broader product categories rather than brand-level ethambutol revenue.

The financial trajectory is therefore best characterized as follows:

Period	Financial profile
Launch and early adoption	Branded prescription product with conventional pharmaceutical margins
Genericization	Sharp price erosion and loss of exclusivity
Mature market	Stable unit demand with low average selling prices
Current market	Procurement-driven revenue, limited brand premium, high sensitivity to supply contracts
Long-term outlook	Volume broadly linked to tuberculosis burden; nominal revenue growth likely limited without price or contract expansion

Revenue can rise even when price declines if a supplier wins government tenders, enters new geographies, or adds fixed-dose combination products. Conversely, a supplier can lose revenue despite stable global demand if it loses procurement contracts or experiences manufacturing interruptions.

The highest-margin opportunities are more likely to come from:

• Contract manufacturing.
• Combination products.
• Regulated-market supply.
• Emergency and stockpile contracts.
• Products with strong quality documentation.
• Integrated tuberculosis portfolios.

Standalone tablets sold through competitive tenders generally have lower margins and limited pricing power.

Which companies are challenging Myambutol’s market position?

Competition comes primarily from generic manufacturers and public-sector suppliers rather than from branded innovators. The relevant competitive set includes manufacturers of:

• Ethambutol hydrochloride tablets.
• Rifampicin-isoniazid-pyrazinamide-ethambutol fixed-dose combinations.
• Pediatric dispersible or dispersible-dose tuberculosis products.
• Tuberculosis medicines approved for international procurement.
• API and finished-dose products supplied to government programs.

The competitive advantage is based on manufacturing scale, regulatory history, World Health Organization prequalification where relevant, reliable API sourcing, and tender performance. Brand recognition for Myambutol has limited value in large public-health purchases.

What generic entry risks exist for Myambutol?

Generic entry is already established, so the principal risk is not a future launch cliff. It is continuing price compression and supplier substitution.

Key risks include:

• Low-cost competition from manufacturers in India, China, and other established generic-production markets.
• Tender losses.
• API shortages or quality failures.
• Product delisting or regulatory noncompliance.
• Substitution by fixed-dose combinations.
• Changes in tuberculosis treatment guidelines.
• Reduced procurement in countries with falling incidence.
• Increased use of susceptibility-directed regimens that remove ethambutol from selected patients.

The main barrier to entry is operational rather than intellectual property. A supplier must meet FDA or other national quality requirements, demonstrate bioequivalence where required, maintain validated manufacturing, and satisfy procurement standards.

What patent litigation and settlement agreements affect Myambutol?

No major current patent litigation or settlement agreement is generally associated with the legacy Myambutol product. The product’s age and generic status reduce the likelihood of commercially material Paragraph IV litigation.

Litigation risk could still arise from:

• A newer fixed-dose combination.
• A manufacturing-process patent.
• Regulatory exclusivity for a specialized formulation.
• Product liability involving optic toxicity.
• Supply or procurement disputes.
• Trademark disputes involving the Myambutol name.

These risks are separate from core ethambutol patent exclusivity and would not normally support a broad branded monopoly.

What is the geographic coverage of the Myambutol market?

Ethambutol demand is concentrated in countries with substantial tuberculosis burdens and active public-health programs. India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and the Democratic Republic of the Congo are among the countries with major tuberculosis burdens identified in WHO reporting.[2]

In the United States and Western Europe, demand is lower in volume but can carry higher regulatory and distribution requirements. Purchases are often made through hospitals, public-health departments, specialist pharmacies, or government channels. In high-burden countries, the largest volumes usually flow through national tuberculosis programs and international procurement mechanisms.

Geographic revenue depends on more than case counts. It also reflects:

• National guideline adoption.
• Domestic manufacturing policy.
• Donor funding.
• Registration status.
• Tender eligibility.
• Local quality requirements.
• Availability of combination products.

What is the outlook for Myambutol?

Myambutol has a stable but low-growth commercial profile. The product is unlikely to generate material branded pharmaceutical expansion without a new formulation, combination product, or procurement strategy. Its underlying market should remain durable because tuberculosis treatment programs continue to require ethambutol in appropriate first-line regimens.

The most credible growth opportunities are volume-based:

1. Expansion of tuberculosis diagnosis and treatment coverage.
2. Increased public-health procurement in high-burden countries.
3. Fixed-dose combination adoption.
4. Pediatric and simplified dosing products.
5. Supply agreements with international procurement agencies.
6. Improved access in regions affected by treatment interruptions.

The main downside risks are persistent price erosion, guideline changes, supplier competition, and declining incidence in some developed markets.

Key Takeaways

• Myambutol is ethambutol hydrochloride, an old, genericized tuberculosis medicine.
• Its original patent and regulatory exclusivity expired decades ago.
• No meaningful current patent barrier or biosimilar risk exists.
• Revenue is procurement-driven and standalone brand sales are not publicly reported in a reliable, audited format.
• Fixed-dose combinations are more commercially important than the legacy Myambutol brand.
• Global tuberculosis incidence supports durable unit demand, but low prices limit revenue growth.
• Manufacturing reliability, regulatory compliance, and tender access are more important than patent protection.
• Paragraph IV litigation and settlement risk are currently limited for the original product.
• The strongest commercial opportunities are in public-sector supply, combination products, and regulated-market manufacturing.

FAQs about Myambutol market and financial prospects

Is Myambutol still commercially available?

Ethambutol hydrochloride remains available through generic and, in some markets, branded products. The availability of the specific Myambutol brand varies by country and supplier.

Does Myambutol have a patent-expiration date?

The original ethambutol patent protection expired many years ago. Current commercial competition is not dependent on a new loss-of-exclusivity event.

Is ethambutol included in fixed-dose tuberculosis combinations?

Yes. Ethambutol is commonly included in fixed-dose combinations with rifampicin, isoniazid, and pyrazinamide for initial treatment of drug-susceptible tuberculosis.

Can a generic manufacturer launch ethambutol without a Paragraph IV challenge?

Yes. Because the core product is long off-patent, a generic applicant does not generally need to defeat a live composition-of-matter patent to enter the market.

What would increase the value of the Myambutol franchise?

The most credible value drivers are procurement wins, reliable supply, regulated-market approvals, pediatric formulations, and fixed-dose combination products rather than higher branded pricing.

References

1. U.S. Food and Drug Administration. (2015). Myambutol (ethambutol hydrochloride) tablets: Prescribing information.
2. World Health Organization. (2024). Global tuberculosis report 2024.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.